Skip to content

Study · Observational study · 2022

4 results

Cerebrolysin Use in Patients with Liver Damage-A Translational Study.

Morega S, Gresita A, Mitran SI, Musat MI, Boboc IKS, Gheorman V, Udristoiu I, Albu CV, Streba CT, Catalin B, Rogoveanu I

Life (Basel, Switzerland)4 Nov 2022Cited by 7 (Europe PMC)

PMID36362945 (opens in a new tab)PMCIDPMC9695462 (opens in a new tab)DOI10.3390/life12111791 (opens in a new tab)PepBankPUB-36362945
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

The treatment of acute life-threatening events in patients suffering from chronic pathologies is problematic, as physicians need to consider multisystemic drug effects. Regarding Cerebrolysin, a Sonic Hedgehog signaling pathway amplifier and one of the few approved neurotrophic treatments for stroke patients, concerns of excessive Hedgehog pathway activation that could accelerate NAFLD progression to cirrhosis seem valid. We investigated stroke patients treated with Cerebrolysin that presented elevated levels of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT). We also investigated the efficiency of Cerebrolysin in reversing the neurogenesis inhibition within the hippocampus in a mouse model of NAFLD by evaluating behavior and histological outcomes. NeuN, BrdU and Iba1 positive signals in the cortex and hippocampus of the animals were also observed. Clinically, Cerebrolysin improved AST levels in a majority of stroke patients with hepatic damage. The same treatment in an experimental setup was able to reverse anxiety-like behavior in MCD mice, reducing their freezing time from 333.61 ± 21.81 s in MCD animals to 229.17 ± 26.28 in treated ones. The use of Cerebrolysin did not improve short-term memory nor rescued cell multiplication in the hippocampus after MCD food intake. Understanding the neuroprotective and neurotrophic effects that drugs have on NAFLD patients can significantly contribute to a suitable therapeutic approach.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyEfficacy outcome

    In stroke patients with hepatic damage, Cerebrolysin improved AST levels in a majority of patients.

    In plain wordsIn stroke patients with liver damage, Cerebrolysin was linked to improved AST levels in most patients.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedAST levels
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Clinically, Cerebrolysin improved AST levels in a majority of stroke patients with hepatic damage.
    1 context sentence
    Summary · context
    We investigated stroke patients treated with Cerebrolysin that presented elevated levels of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In MCD mice, Cerebrolysin reduced freezing time versus untreated MCD animals (333.61 ± 21.81 s versus 229.17 ± 26.28).

    In plain wordsIn mice with fatty liver disease, Cerebrolysin reduced freezing time compared with MCD animals.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseFreezing time
    Study

    mousen: not reported in source

    NAFLD MCD mice
    Comparator
    MCD animals
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Measurements

    Freezing time
    333.61 s
    MCD animals
    Freezing time
    229.17 s
    treated animals

    Source sentences

    Summary
    The same treatment in an experimental setup was able to reverse anxiety-like behavior in MCD mice, reducing their freezing time from 333.61 ± 21.81 s in MCD animals to 229.17 ± 26.28 in treated ones.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In MCD mice, Cerebrolysin did not improve short-term memory.

    In plain wordsIn mice, Cerebrolysin did not improve short-term memory.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeShort-term memory
    Study

    mousen: not reported in source

    NAFLD MCD mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of Cerebrolysin did not improve short-term memory nor rescued cell multiplication in the hippocampus after MCD food intake.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In MCD mice, Cerebrolysin did not rescue hippocampal cell multiplication after MCD food intake.

    In plain wordsIn mice, Cerebrolysin did not restore hippocampal cell multiplication after MCD food intake.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeHippocampal cell multiplication
    Study

    mousen: not reported in source

    NAFLD MCD mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of Cerebrolysin did not improve short-term memory nor rescued cell multiplication in the hippocampus after MCD food intake.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.